Compare Invesco DB Commodity Index Tracking Fund (DBC) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Commodity Index Tracking Fund vs Nuwellis Inc — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $33.08 (market cap $1.92B), while Nuwellis Inc trades at $0.7 (market cap $2.20M). The key difference: Invesco DB Commodity Index Tracking Fund is far larger — about 872.7× Nuwellis Inc's market cap, and Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Commodity Index Tracking Fund for 61 Days and Nuwellis Inc for 26 Days on average.
| DBC | NUWE | |
|---|---|---|
Market Cap | $1.92B | $2.20M |
Volume | 1,375,556 | 121,544 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $33.68 | $146.65 |
52-Week Low | $22.07 | $0.68 |
Typical Hold Time | 61 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBC trades at $32.51, down 0.55% today, with a bullish technical signal from moving averages. The company reported $82.59M revenue and $22.38M net income for 2024, showing improved profitability with a 27.1% margin. Cash flow from operations was strong at $431.54M, though total assets declined from $2.7B in 2021 to $1.29B currently. Technical indicators show support at $32 and resistance at $33.
DBC demonstrates solid operational cash generation despite asset base contraction. The zero-debt balance sheet provides financial stability, but declining revenue from 2023's $108M raises growth concerns. Current valuation metrics remain undisclosed, requiring deeper analysis. The stock's technical strength suggests near-term upside potential if fundamental performance stabilizes.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
